Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 4Completed 2Terminated 1Suspended 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lymphoma, B-Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × abivertinib × Clear all
NCT02330367 2021-09-10

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1/2 Unknown
368 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03856697 2019-02-27

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 3 Unknown
406 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT03300115 2019-02-19

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 2 Unknown
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03060850 2019-02-01

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1 Unknown
184 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡